These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 17175117)

  • 1. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
    Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
    Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
    Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer.
    Gellert GC; Dikmen ZG; Wright WE; Gryaznov S; Shay JW
    Breast Cancer Res Treat; 2006 Mar; 96(1):73-81. PubMed ID: 16319992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.
    Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL
    Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor.
    Dikmen ZG; Gellert GC; Jackson S; Gryaznov S; Tressler R; Dogan P; Wright WE; Shay JW
    Cancer Res; 2005 Sep; 65(17):7866-73. PubMed ID: 16140956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.
    Mo Y; Gan Y; Song S; Johnston J; Xiao X; Wientjes MG; Au JL
    Cancer Res; 2003 Feb; 63(3):579-85. PubMed ID: 12566299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.
    Herbert BS; Gellert GC; Hochreiter A; Pongracz K; Wright WE; Zielinska D; Chin AC; Harley CB; Shay JW; Gryaznov SM
    Oncogene; 2005 Aug; 24(33):5262-8. PubMed ID: 15940257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
    Chen Z; Koeneman KS; Corey DR
    Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent.
    Gryaznov SM; Jackson S; Dikmen G; Harley C; Herbert BS; Wright WE; Shay JW
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1577-9. PubMed ID: 18066830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
    Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
    Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
    Herbert BS; Pongracz K; Shay JW; Gryaznov SM
    Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G-quadruplex stabilizer 3,6-bis(1-methyl-4-vinylpyridinium)carbazole diiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells.
    Huang FC; Chang CC; Lou PJ; Kuo IC; Chien CW; Chen CT; Shieh FY; Chang TC; Lin JJ
    Mol Cancer Res; 2008 Jun; 6(6):955-64. PubMed ID: 18515756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel.
    Goldblatt EM; Gentry ER; Fox MJ; Gryaznov SM; Shen C; Herbert BS
    Mol Cancer Ther; 2009 Jul; 8(7):2027-35. PubMed ID: 19509275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab.
    Goldblatt EM; Erickson PA; Gentry ER; Gryaznov SM; Herbert BS
    Breast Cancer Res Treat; 2009 Nov; 118(1):21-32. PubMed ID: 18853252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells.
    Dikmen ZG; Wright WE; Shay JW; Gryaznov SM
    J Cell Biochem; 2008 May; 104(2):444-52. PubMed ID: 18044713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase.
    Jackson SR; Zhu CH; Paulson V; Watkins L; Dikmen ZG; Gryaznov SM; Wright WE; Shay JW
    Cancer Res; 2007 Feb; 67(3):1121-9. PubMed ID: 17283146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.
    Ward RJ; Autexier C
    Mol Pharmacol; 2005 Sep; 68(3):779-86. PubMed ID: 15939802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells.
    Kim JH; Kim JH; Lee GE; Kim SW; Chung IK
    Biochem J; 2003 Jul; 373(Pt 2):523-9. PubMed ID: 12689331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
    Kelland L
    Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.